Top

Published in:

01-05-2011 | Translational Research and Biomarkers

Influence of A9 Region Mutation in EphB2 Gene in the Prognosis of Patients with Colorectal Adenocarcinoma

Authors: M. Vidaurreta, PhD, S. Rafael, PhD, S. Veganzones, PhD, V. de la Orden, PhD, C. Fernández, MD, R. Gómez-Casaseca, BD, J. Cerdán, MD, M. Maestro, PhD

Published in: Annals of Surgical Oncology | Issue 5/2011

Abstract

Background

EphB2 is a transmembrane glycoprotein implicated in the regulation of cell growth, differentiation, and motility. It has been proposed as a tumor suppressor gene, and the role of EphB2 protein in tumorogenesis has been demonstrated. The aim of this study was to test the influence of mutation of A9 region in EphB2 gene in the prognosis of patients with sporadic CCR.

Materials and Methods

A total of 473 patients with colorectal cancer were included. A9 region in exon 17 of EphB2 was amplified using specific primer and analyzed using Genescan. All mutations were confirmed by direct sequencing.

Results

EphB2 mutation was detected in 13 of the 473 patients (2.7%). Mutation of EphB2 showed association with tumor site, 12 of 13 mutations were proximal tumors (P < 0.001). EphB2 mutation confers better prognosis in the adenocarcinoma group; 100% of patients carrying the mutation survived and were disease free after 72 months (P = 0.02 and 0.03, respectively).

Conclusions

Despite the low frequency of EphB2 gene, we got promising results. It would be very interesting to increase the population size to verify our results. If these findings are confirmed, EphB2 could help discriminate patients with adenocarcinoma with different prognosis and to improve the election of the most suitable treatment in each case.

Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–43.PubMedCrossRef

Ferlay J, Bray F, Pisan P, Parkin DM. Globocan 2000: cancer incidence, mortality and prevalence worldwide. France: IARC Press; 2001.

Skibber JM, Minsky BD, Hoff PM. Cancer of the colon. Chapter 33.7. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer Principles and Practice of Oncology. 6th ed. Lippincott Williams and Wilkins, Philadelphia, PA, 2001.

Cancer Trends Progress Report—2009/2010 Update, National Cancer Institute, NIH, DHHS, Bethesda, MD, April 2010.

Vogelstein B, Fearon E, Hamilton S, Kern S, Preisinger A, Leppert M, et al. Genetic alterations during colorectal tumor development. N Engl J Med. 1988;319:525–32.PubMedCrossRef

Batlle E, Henderson JT, Beghtel H, van den Born MM, Sancho E, Huls G, et al. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell. 2002;111:251–63.PubMedCrossRef

Eph Nomenclature Committee, Unified nomenclature for Eph family receptors and their ligands, the ephrins. Cell. 1997;90:403–4.

Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355–65.PubMedCrossRef

Batlle E, Bacani J, Gegthel H, Jonkheer S, Gregorieff A, van de Born M, et al. EphB receptor activity suppresses colorectal cancer progression. Nature. 2005;435:1126–30.PubMedCrossRef

10.

Ikegaki N, Tang XX, Liu XG, Biegel JA, Allen C, Yoshioka EP, et al. Molecular characterization and chromosomal localization of DRT (EPHT3): adevelopmentally regulated human protein-tyrosine kinase gene of the EPH family. Hum. Mol Gen. 1995;4:2033–45.PubMedCrossRef

11.

Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ, et al. Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res. 2005;65:10170–73.PubMedCrossRef

12.

Cerdán J. Seguimiento de los pacientes intervenidos de cáncer colorrectal. Rev Cancer. 1997;11:32–41.

13.

Davalos V, Dopeso H, Velho S, Ferreira AM, Cirnes L, Diaz-Chico N, et al. High EphB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. Oncogene. 2007;26:308–11.PubMedCrossRef

14.

Guo DL, Zhang J, Yues ST, Tsui WY, Chan AS, Ho C, et al. Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumors. Carcinogenesis. 2006;27:454–64.PubMedCrossRef

15.

Lugli A, Spichtin H, Maurer R, Mirlacher M, Kiefer J, Huusko P, et al. EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancer. Clin Cancer Res. 2005;11:6450–8.PubMedCrossRef

16.

Song JH, Kim CJ, Cho YG, Kwak HH, Nam SW, Yoo NJ, et al. Genetic and epigenetic analysis of the EPHB2 gene in gastric cancers. APMIS. 2007;115:164–8.PubMedCrossRef

17.

Maestro ML, Vidaurreta M, Sanz-Casla MT, Rafael S, Veganzones S, Martínez A, et al. Role of the BRAF mutations in the microsatellite instability genetic pathway in sporadic colorectal cancer. Ann Surg Oncol. 2007;14:1229–36.PubMedCrossRef

Title: Influence of A9 Region Mutation in EphB2 Gene in the Prognosis of Patients with Colorectal Adenocarcinoma
Authors: M. Vidaurreta, PhD
S. Rafael, PhD
S. Veganzones, PhD
V. de la Orden, PhD
C. Fernández, MD
R. Gómez-Casaseca, BD
J. Cerdán, MD
M. Maestro, PhD
Publication date: 01-05-2011
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 5/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-010-1448-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Influence of A9 Region Mutation in EphB2 Gene in the Prognosis of Patients with Colorectal Adenocarcinoma

Abstract

Background

Materials and Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Materials and Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2011

MDM2 is Overexpressed and Regulated by the Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Squamous Cell Carcinoma of Esophagus

Inadequate Cytology of Thyroid Nodules. Repeat It or Live With It

Tumor Size Remains Key for Prediction of Hepatocellular Carcinoma Recurrence after Liver Transplantation

Central Compartment Reoperation for Recurrent/Persistent Differentiated Thyroid Cancer: Patterns of Recurrence, Morbidity, and Prediction of Postoperative Hypocalcemia

Overexpression of Long Non-coding RNA HOTAIR Predicts Tumor Recurrence in Hepatocellular Carcinoma Patients Following Liver Transplantation

Is pT2 Subclassification Feasible to Predict Patient Outcome in Colorectal Cancer?